Dr. Stromatt has conducted over 55 Phase 1 to Phase 4 clinical trials in a wide variety of clinical indications, including oncology, rheumatology, pulmonology, gastroenterology, and neurology. In the field of neurology, he ran clinical trials with a novel growth factor for Lou Gehrig’s disease, or amyotrophic lateral sclerosis. He has worked on various regulatory filings including INDs, NDAs, BLAs, and MAAs. Additionally, he has experience in medical affairs with extensive market and brand management support.
Currently, Dr. Stromatt is the Chief Medical Officer at Emergent BioSolutions in Seattle, WA – a biotechnology company focused on oncology, autoimmune disease, and infectious diseases.